ACXP - CIK 0001736243
The table below shows Acurx Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $1.83M | $5.40M | $6.04M | $4.75M | $2.03M | $2.20M |
| SG&A | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| $208.27K |
| - |
| Operating income | -$8.09M | -$14.12M | - | - | - | - |
| Income tax | - | - | - | $0.00 | - | $0.00 |
| Net income | -$7.97M | -$14.10M | -$14.58M | -$12.09M | -$12.75M | -$4.60M |
| EPS (diluted) | -$5.32 | -$17.45 | -$1.15 | -$1.12 | -$1.49 | -$0.74 |